Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.
Patel RB, Hernandez R, Carlson P, Grudzinski J, Bates AM, Jagodinsky JC, Erbe A, Marsh IR, Arthur I, Aluicio-Sarduy E, Sriramaneni RN, Jin WJ, Massey C, Rakhmilevich AL, Vail D, Engle JW, Le T, Kim K, Bednarz B, Sondel PM, Weichert J, Morris ZS.
Patel RB, et al. Among authors: grudzinski j.
Sci Transl Med. 2021 Jul 14;13(602):eabb3631. doi: 10.1126/scitranslmed.abb3631.
Sci Transl Med. 2021.
PMID: 34261797
Free PMC article.